Skip to main content
SpringerLink
Log in

Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson’s Disease

  • Protocol
  • First Online:
Book cover Kinase Inhibitors

Part of the book series: Methods in Molecular Biology ((MIMB,volume 795))

Abstract

Mutations in the LRRK2 (Leucine-Rich Repeat Kinase 2) gene are the most common cause of autosomal dominant Parkinson’s disease. LRRK2 has multiple functional domains including a kinase domain. The kinase activity of LRRK2 is implicated in the pathogenesis of Parkinson’s disease. Developing an assay to understand the mechanisms of LRRK2 kinase activity is important for the development of pharmacologic and therapeutic applications. Here, we describe how to measure in vitro LRRK2 kinase activity and its inhibition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24, 197–211.

    Article  PubMed  Google Scholar 

  2. Morris, H. R. (2005) Genetics of Parkinson’s disease. Ann Med 37, 86–96.

    Article  PubMed  CAS  Google Scholar 

  3. Lesage, S., and Brice, A. (2009) Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48–59.

    Article  PubMed  CAS  Google Scholar 

  4. Elbaz, A. (2008) LRRK2: bridging the gap between sporadic and hereditary Parkinson’s disease. Lancet Neurol. 7, 562–564.

    Article  PubMed  Google Scholar 

  5. Haugarvoll, K., Rademakers, R., Kachergus, J. M., Nuytemans, K., Ross, O. A., Gibson, J. M., Tan, E. K., Gaig, C., Tolosa, E., Goldwurm, S., Guidi, M., Riboldazzi, G., Brown, L., Walter, U., Benecke, R., Berg, D., Gasser, T., Theuns, J., Pals, P., Cras, P., De Deyn, P. P., Engelborghs, S., Pickut, B., Uitti, R. J., Foroud, T., Nichols, W. C., Hagenah, J., Klein, C., Samii, A., Zabetian, C. P., Bonifati, V., Van Broeckhoven, C., Farrer, M. J., and Wszolek, Z. K. (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70, 1456–1460.

    Article  PubMed  CAS  Google Scholar 

  6. Change, N., Mercier, G., and Lucotte, G. (2008) Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects. Genet. Test. 12, 333–339.

    Article  PubMed  CAS  Google Scholar 

  7. Tan, E. K., Tan, L. C., Lim, H. Q., Li, R., Tang, M., Yih, Y., Pavanni, R., Prakash, K. M., Fook-Chong, S., and Zhao, Y. (2008) LRRK2 R1628P increases risk of Parkinson’s disease: replication evidence. Hum. Genet. 124, 287–288.

    Article  PubMed  CAS  Google Scholar 

  8. Tomiyama, H., Mizuta, I., Li, Y., Funayama, M., Yoshino, H., Li, L., Murata, M., Yamamoto, M., Kubo, S., Mizuno, Y., Toda, T., and Hattori, N. (2008) LRRK2 P755L variant in sporadic Parkinson’s disease. J. Hum. Genet. 53, 1012–1015.

    Article  PubMed  CAS  Google Scholar 

  9. Floris, G., Cannas, A., Solla, P., Murru, M. R., Tranquilli, S., Corongiu, D., Rolesu, M., Cuccu, S., Sardu, C., Marrosu, F., and Marrosu, M. G. (2009) Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: Importance of G2019S and R1441C mutations in sporadic Parkinson’s disease patients. Parkinsonism Relat. Disord. 15, 277–280.

    Article  PubMed  Google Scholar 

  10. Gorostidi, A., Ruiz-Martinez, J., Lopez de Munain, A., Alzualde, A., and Marti Masso, J. F. (2009) LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 10, 157–159.

    Article  PubMed  CAS  Google Scholar 

  11. Patra, B., Parsian, A. J., Racette, B. A., Zhao, J. H., Perlmutter, J. S., and Parsian, A. (2009) LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson’s disease. Parkinsonism Relat. Disord. 15, 175–180.

    Article  PubMed  Google Scholar 

  12. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, A. J., Pfeiffer, R. F., Patenge, N., Carbajal, I. C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D. W., Meitinger, T., Strom, T. M., Wszolek, Z. K., and Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607.

    Article  PubMed  CAS  Google Scholar 

  13. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., Ahmad, R., Miller, D. W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R. J., Harvey, K., and Cookson, M. R. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329–341.

    Article  PubMed  CAS  Google Scholar 

  14. Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231–1233.

    Article  PubMed  CAS  Google Scholar 

  15. Cookson, M. R., Dauer, W., Dawson, T., Fon, E. A., Guo, M., and Shen, J. (2007) The roles of kinases in familial Parkinson’s disease. J. Neurosci. 27, 11865–11868.

    Article  PubMed  CAS  Google Scholar 

  16. West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K. L., Dawson, V. L., and Dawson, T. M. (2007) Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16 pp. 223–232.

    Article  PubMed  CAS  Google Scholar 

  17. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102, 16842–16847.

    Article  PubMed  CAS  Google Scholar 

  18. Gloeckner, C. J., Kinkl, N., Schumacher, A., Braun, R. J., O’Neill, E., Meitinger, T., Kolch, W., Prokisch, H., and Ueffing, M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223–232.

    Article  PubMed  CAS  Google Scholar 

  19. Covy, J. P., and Giasson, B. I. (2009) Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem. Biophys. Res. Commun. 378, 473–477.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the USPHS P50NS038377 and R01NS048206. T.M.D. is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases at Johns Hopkins.

Author information

Authors and Affiliations

  1. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Byoung Dae Lee

  2. Cell and Molecular Medicine Graduate Training Program, Johns Hopkins University School of Medicine, Baltimore, MA, USA

    Xiaojie Li

  3. Department of Neurology, Neuroregeneration and Stem Cell Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MA, USA

    Ted M. Dawson

  4. Solomon H. Snyder Department of Neuroscience, Neuroregeneration and Stem Cell Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MA, USA

    Ted M. Dawson

  5. Department of Neurology, Neuroregeneration and Stem Cell Program, Institute for Cell Engineering, Baltimore, MA, USA

    Valina L. Dawson

  6. Solomon H. Snyder Department of Neuroscience, Neuroregeneration and Stem Cell Program, Institute for Cell Engineering, Baltimore, MA, USA

    Valina L. Dawson

  7. Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MA, USA

    Valina L. Dawson

Authors
  1. Byoung Dae Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaojie Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ted M. Dawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valina L. Dawson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valina L. Dawson .

Editor information

Editors and Affiliations

  1. LS für Proteomik und Bioanalytik, Technische Universität München, Emil Erlenmeyer Forum 5, Freising, 85354, Germany

    Bernhard Kuster

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Lee, B.D., Li, X., Dawson, T.M., Dawson, V.L. (2012). Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson’s Disease. In: Kuster, B. (eds) Kinase Inhibitors. Methods in Molecular Biology, vol 795. Humana Press. https://doi.org/10.1007/978-1-61779-337-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-337-0_3

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-336-3

  • Online ISBN: 978-1-61779-337-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation